Versigent PLC (VGNT) Key Metrics
VGNT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.13B
- Enterprise value
- $5.14B
- P/E (TTM)
- 6.5
- Forward P/E
- 5.8
- PEG ratio
- —
- Price / sales
- 0.3
- Price / book
- 38.5
- EV / EBITDA
- 5.7
- Dividend yield
- 1.18% $0.52 a year
- Beta
- —
VGNT key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsVGNT returns How much profit the business earns on the capital it uses.
VGNT per-share figures Results divided by the shares outstanding at year-end.
VGNT financial health Debt, liquidity and how easily interest is covered.
VGNT efficiency & capital use Working capital cycle and where the cash goes.
VGNT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VGNT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VGNT key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Per share | ||||
| Revenue per share | $124.11 | $116.95 | $124.31 | $112.81 |
| Earnings per share | $7.43 | $5.74 | $5.95 | $6.39 |
| Operating cash flow per share | $9.02 | $9.95 | $2.53 | $8.53 |
| Free cash flow per share | $6.77 | $7.05 | −$0.90 | $5.39 |
| Cash per share | $10.74 | $2.83 | $2.98 | — |
| Book value per share | $23.22 | $21.45 | $25.19 | — |
| Tangible book value per share | $23.13 | $21.35 | $25.05 | — |
| Capex per share | $2.25 | $2.90 | $3.43 | $3.14 |
| Debt per share | $9.82 | $5.90 | $3.84 | — |
| Shares outstanding | 71.0M | 71.0M | 71.0M | 71.0M |
| Change in shares outstanding | 0.0% | 0.0% | 0.0% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | 33.3% | 24.6% | 23.6% | — |
| Return on invested capital (ROIC) | 40.3% | 27.4% | 28.1% | — |
| Return on assets (ROA) | 11.6% | 9.5% | 9.6% | — |
| Return on tangible assets | 10.6% | 9.9% | 9.6% | — |
| Free cash flow margin | 5.5% | 6.0% | −0.7% | 4.8% |
| Income quality (OCF / net income) | 1.21 | 1.73 | 0.43 | 1.33 |
| Financial health | ||||
| Total debt | $698.0M | $419.0M | $273.0M | — |
| Cash & short-term investments | $763.0M | $201.0M | $212.0M | — |
| Net debt | −$65.0M | $218.0M | $61.0M | — |
| Debt / equity | 0.42 | 0.27 | 0.15 | — |
| Debt / assets | 0.14 | 0.10 | 0.06 | — |
| Net debt / EBITDA | −0.07 | 0.30 | 0.07 | — |
| Current ratio | 1.50 | 1.16 | 1.28 | — |
| Quick ratio | 1.14 | 0.83 | 0.91 | — |
| Working capital | $1.08B | $343.0M | $588.0M | — |
| Invested capital | $1.58B | $1.74B | $1.85B | — |
| Tangible asset value | $1.83B | $1.72B | $1.98B | — |
| Net current asset value | $104.0M | $20.0M | $250.0M | — |
| Graham number | $62.32 | $52.65 | $58.10 | — |
| Graham net-net per share | −$10.52 | −$10.29 | −$8.07 | — |
| Capital allocation | ||||
| Capex / revenue | 1.8% | 2.5% | 2.8% | 2.8% |
| Capex / operating cash flow | 25.0% | 29.1% | 135.6% | 36.8% |
| Capex / depreciation | 0.70 | 1.02 | 1.19 | 1.17 |
| Stock-based compensation / revenue | 0.4% | 0.3% | 0.3% | 0.3% |
| R&D / revenue | 3.1% | 3.4% | 3.1% | 3.1% |
| SG&A / revenue | 4.8% | 4.9% | 4.4% | 4.4% |
| Efficiency | ||||
| Days sales outstanding | 66.1 | 69.8 | 68.9 | — |
| Days of inventory on hand | 35.0 | 36.6 | 36.1 | — |
| Days payables outstanding | 67.5 | 69.4 | 69.2 | — |
| Cash conversion cycle (days) | 33.5 | 37.0 | 35.7 | — |
| Receivables turnover | 5.53 | 5.23 | 5.30 | — |
| Payables turnover | 5.40 | 5.26 | 5.27 | — |
| Inventory turnover | 10.44 | 9.98 | 10.11 | — |
| Asset turnover | 1.93 | 1.94 | 2.00 | — |
| Average receivables | $1.60B | $1.59B | $1.67B | — |
| Average payables | $1.43B | $1.40B | $1.47B | — |
| Average inventory | $740.5M | $738.0M | $767.0M | — |
| Intangibles / total assets | 0.1% | 0.2% | 0.2% | — |
Computed from VGNT's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VGNT valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 6.5 and the forward P/E is 5.8. Versigent earned a return on equity of 33.3% and a return on invested capital of 40.3% in fiscal 2025. It ended the year with $698.0 million of debt and $763.0 million in cash and short-term investments, a net cash position of $65.0 million.
See the VGNT income statement, the VGNT chart for price history, or the VGNT stock overview for the latest quote and news.
VGNT key metrics FAQ
What is Versigent's P/E ratio?
Versigent's trailing P/E ratio is 6.5 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 5.8. At the end of fiscal 2025 it was —.
What is Versigent's return on equity?
Versigent's return on equity (ROE) was 33.3% in fiscal 2025: net income of $528.0 million on average shareholders' equity of $1.6 billion.
What is Versigent's ROIC?
Versigent's return on invested capital was 40.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Versigent have?
Versigent had total debt of $698.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.42 and more cash than debt.
What is Versigent's current ratio?
Versigent's current ratio was 1.50 at the end of fiscal 2025: current assets were 1.50 times current liabilities.